Springer Seminars in Immunopathology

, Volume 15, Issue 1, pp 51–73 | Cite as

Can anti-IgE be used to treat allergy?

  • F. M. Davis
  • L. A. Gossett
  • K. L. Pinkston
  • R. S. Liou
  • L. K. Sun
  • Y. W. Kim
  • N. T. Chang
  • T. W. Chang
  • K. Wagner
  • J. Bews
  • V. Brinkmann
  • H. Towbin
  • N. Subramanian
  • C. Heusser

Summary and conclusion

A summary of the properties of CGP 51901 is shown in Table 3. On the basis of its binding to IgE and IgE-secreting cells and its activity in vitro and in vivo, CGP 51901 is expected to be able to decrease serum IgE by direct clearance of IgE and by reduction of the numbers and productivity of IgE-secreting cells. The end result of reduction of IgE in the circulation and on mast cells is expected to be the attenuation of IgE-mediated reactions and the improvement in allergy symptoms. The effective serum concentration of CGP 51901 is expected to be in the range 1–10 μg/ml. Because CGP 51901 is an antibody specific for IgE, it is expected to be highly selective in its activity. Because IgE does not appear to be essential and because CGP 51901 has been rigorously tested to confirm its non-anaphylactic nature, this treatment is not expected to have any adverse effects. Therefore, CGP 51901 is expected to be safe and to have a good probability of being effective when it is tested in human clinical trials.


Adverse Effect Clinical Trial Internal Medicine Mast Cell Serum Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beatty JD, Beatty BG, Vlahos WG (1987) Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100:173Google Scholar
  2. 2.
    Bergstedt-Lindqvist S, Moon H-B, Persson U, Müller G, Heusser C, Severinson E (1988) Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur J Immunol 18:1073Google Scholar
  3. 3.
    Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351Google Scholar
  4. 4.
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG (1989) Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320:271PubMedGoogle Scholar
  5. 5.
    Chang TW (1990) Monoclonal antibodies specific for IgE-secreting B lymphocytes. ICSU Short Reports 10:188Google Scholar
  6. 6.
    Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan DW Jr, Hamilton RG (1990) Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 8:122Google Scholar
  7. 7.
    Coffman RL, Carty J (1986) A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-γ. J Immunol 136:949Google Scholar
  8. 8.
    Davis FM, Gossett LA, Chang TW (1991) An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation. Bio/Technology 9:53Google Scholar
  9. 9.
    Delespesse G, Sarfati M, Hofstetter H (1989) Human IgE-binding factors. Immunol Today 10:159Google Scholar
  10. 10.
    Eisen HN (1980) Antibody-mediated (immediate-type) hypersensitivity. In: Davis BD, Dulbecco R, Eisen HN, Ginsberg HS (eds) Microbiology. Harper & Row, Philadelphia, pp 468–492Google Scholar
  11. 11.
    Finkelman FD, Katona LM, Urban JF Jr, Snapper CM, Ohara J, Paul WE (1986) Suppression of in vivo polyclonal IgE response by monoclonal antibody to the lymphocyte B cell stimulatory factor-1. Proc Natl Acad Sci USA 83:9675Google Scholar
  12. 12.
    Finkelman FD, Holmes J, Katona IM, Urban JF Jr, Bechman MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE (1990) Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8:303Google Scholar
  13. 13.
    Frick OL (1987) Immediate hypersensitivity. In: Sites DP, Stobo JD, Wells JV (eds) Basic and clinical immunology, 6th edn. Appleton and Lange, Norwalk, pp 197–227Google Scholar
  14. 14.
    Gillespie E, Lichtenstein LM (1972) Histamine release from human leukocytes: studies with deuterium oxide, colchicine and cytochalasin B. J Clin Invest 51:2941Google Scholar
  15. 15.
    Gordon J, Flores-Romo L, Cairns JA, Millsum MJ, Lane PJ, Johnson GD, MacLennon ICM (1989) CD23: a multifunctional receptor/lymphokine? Immunol Today 10:153Google Scholar
  16. 16.
    Haba S, Nisonoff A (1990) Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc Natl Acad Sci USA 87:3363Google Scholar
  17. 17.
    Heusser ChH, Bews J, Brinkmann V, Delespesse G, Kilchherr E, Ledermann F, LeGros G, Wagner K (1991) New concepts of IgE regulation. Int Arch Allergy Appl Immunol 94:1Google Scholar
  18. 18.
    Ishida N, Ueda S, Hayashida H, Miyata T, Honjo T (1982) The nucleotide sequence of the mouse immunoglobulin epsilon gene: comparison with the human epsilon gene sequence. EMBO J 1:1117Google Scholar
  19. 19.
    Ishizaka K (1988) IgE-binding factors and regulation of the IgE antibody response. Annu Rev Immunol 6:513Google Scholar
  20. 20.
    Ishizaka K, Ishizaka T (1989) Allergy. In: Paul WE (ed) Fundamental Immunology, 2nd edn. Raven Press, New York, pp 867–888Google Scholar
  21. 21.
    Ishizaka T, Ishizaka K (1984) Activation of mast cells for mediator release through IgE receptors. Prog Allergy 34:188Google Scholar
  22. 22.
    Katona IM, Urban JF Jr, Kang SS, Paul WE, Finkelman FD (1991) IL-4 requirements for the generation of secondary in vivo IgE responses. J Immunol 146:4215Google Scholar
  23. 23.
    Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Seeher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AF (1991) Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 51:5461Google Scholar
  24. 24.
    Kuhn R, Rajewsky K, Muller W (1991) Generation and analysis of IL-4 deficient mice. Science 254:707Google Scholar
  25. 25.
    Levy DA, Chen J (1970) Healthy IgE-deficient person. N Engl J Med 283:541Google Scholar
  26. 26.
    Lichtenstein LM, Kagey-Sobotka A, White JM, Hamilton RG (1992) Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors. J Immunol 148:3929Google Scholar
  27. 27.
    Liou RS, Rosen EM, Fung MSC, Sun NC, Sun C, Gordon W, Chang NT, Chang TW (1989). A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. J Immunol 143:3967Google Scholar
  28. 28.
    LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220Google Scholar
  29. 29.
    MacGlashan DW Jr, Peters SP, Warner J, Lichtenstein LM (1986) Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol 136:2231Google Scholar
  30. 30.
    Magnusson CGM, Johansson SGO (1989) Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE. Clin Rev Allergy 7:73Google Scholar
  31. 31.
    Marshall JS, Bell EB (1985) Induction of an auto-anti-IgE response in rats. I. Effects on serum IgE concentrations. Eur J Immunol 15:272Google Scholar
  32. 32.
    Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R (1986) The receptor with high affinity for immunoglobulin E. Annu Rev Immunol 4:419Google Scholar
  33. 33.
    Moqbel R, Pritchard DI (1990) Parasites and allergy: evidence for a “cause and effect” relationship. Clin Exp Allergy 20:611Google Scholar
  34. 34.
    National Heart, Lung and Blood Institute (1991) National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. IV. Overview of approaches to asthma therapy. J Allergy Clin Immunol 88:451Google Scholar
  35. 35.
    NIAID (1991) NIAID Profile Fiscal Year 1990. National Institutes of Health, Bethesda, p 77Google Scholar
  36. 36.
    Paul WE, Ohara J (1987) B-cell stimulatory factor-I/interleukin 4. Annu Rev Immunol 5:429PubMedGoogle Scholar
  37. 37.
    Rocklin RE, David J (1991) Immediate hypersensitivity. In: Rubenstein E, Federman DD (eds) Scientific American medicine, Scientific American, New York, pp 1–14, 33–35Google Scholar
  38. 38.
    Rousseaux-Prevost R, Rousseaux J, Bazin H (1987) Studies of the IgE binding site to rat mast cell receptor with proteolytic fragments and with a monoclonal antibody directed against epsilon heavy chain: evidence that the combining sites are located in the Cɛ3 domain. Mol Immunol 24:187Google Scholar
  39. 39.
    Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM (1990) Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon-gamma-independent mechanism. J Exp Med 171:115Google Scholar
  40. 40.
    Sakoyama Y, Hong KJ, Byun SM, Hisajami H, Ueda S, Yaoita Y, Hayashida H, Miyata T, Honjo T (1987) Nucleotide sequences of immunoglobulin genes of chimpanzee and orangutan: DNA molecular clock and hominid evolution. Proc Natl Acad Sci USA 84:1080Google Scholar
  41. 41.
    Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF (1992) Phase I trial of the chimeric anti-GD2 monoclonal antibody ch 14.18 in patients with malignant melanoma. Hum Antibod Hybridomas 3:19Google Scholar
  42. 42.
    Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Hollaway MD (1991) Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 325:1067Google Scholar
  43. 43.
    Siraganian R (1988) Mast cells and basophils. In: Gallin JI, Goldstein IM, Snyderman R (eds) Inflammation: basic principles and clinical correlates. Raven Press, New York, pp 513–542Google Scholar
  44. 44.
    Siraganian RP, Hook WA (1980) Histamine-release and assay methods for the study of human allergy. In: Rose NR, Friedman H (eds) Manual of clinical chemistry, 2nd edn. American Society for Microbiology, Washington D.C., pp 808–821Google Scholar
  45. 45.
    Souillet G, Roussel F, DeVries J (1989) Alpha-interferon treatment of a patient with hyper IgE syndrome. Lancet 1:1384Google Scholar
  46. 46.
    Spiegelberg HL (1984) Structure and function of Fc receptors for IgE on lymphocytes, monocytes, and macrophages. Adv Immunol 35:61Google Scholar
  47. 47.
    Statistics of Allergy Diseases and Immunology (1992) American Academy of Allergy and Immunology, MilwaukeeGoogle Scholar
  48. 48.
    Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852Google Scholar
  49. 49.
    Sun LK, Liou RS, Sun NC, Gossett LA, Sun C, Davis FM, MacGlashan DW Jr, Chang TW (1991) Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity. J Immunol 146:199Google Scholar
  50. 50.
    Thena DM, Marshall JS, Haeney MR, Bell EB (1989) A survey of nonatopic and atopic children and adults for the presence of anti-IgE autoantibodies. Clin Immunol Immunopathol 53:40Google Scholar
  51. 51.
    Thyphronitis G, Max EE, Finkelman FD (1991) Generation and cloning of stable human IgE-secreting cells that have rearranged the Cɛ gene. J Immunol 146:1496Google Scholar
  52. 52.
    Walker MR, Woof JM, Brüggemann M, Jefferis R, Burton DR (1989) Interaction of human IgG chimeric antibodies with the human FcRI and FcRII receptors: requirements for antibody-mediated host cell-target cell interaction. Mol Immunol 26:403Google Scholar
  53. 53.
    Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293Google Scholar
  54. 54.
    Yelton DE (1991) Clinical experience with the L6 anti-carcinoma antibody. In: Antibody engineering. IBC USA Conferences, South NatickGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • F. M. Davis
    • 1
  • L. A. Gossett
    • 1
  • K. L. Pinkston
    • 1
  • R. S. Liou
    • 1
  • L. K. Sun
    • 1
  • Y. W. Kim
    • 1
  • N. T. Chang
    • 1
  • T. W. Chang
    • 1
  • K. Wagner
    • 2
  • J. Bews
    • 2
  • V. Brinkmann
    • 2
  • H. Towbin
    • 2
  • N. Subramanian
    • 2
  • C. Heusser
    • 2
  1. 1.Tanox Biosystems, Inc.HoustonUSA
  2. 2.Pharma Research, CIBA-GEIGY LimitedBaselSwitzerland

Personalised recommendations